Lakefront Biotherapeutics (LKFT) EPS (Weighted Average and Diluted) (2015 - 2026)
Lakefront Biotherapeutics (LKFT) reported EPS (Weighted Average and Diluted) of $15960.8 for Q1 2026, up 109.66% year-over-year from $7612.7 in Q1 2025, and up 134371.98% quarter-over-quarter from $11.87 in Q4 2025.
Lakefront Biotherapeutics (LKFT) EPS (Weighted Average and Diluted) (2015 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has 12 years of EPS (Weighted Average and Diluted) data on file, last reported at $15960.8 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at $15960.8, up 109.66% year-over-year; the trailing twelve-month figure through Dec 2025 was $11.87 (up 2990.63% YoY), and the FY2025 annual result was $5.67, up 373.66% from the prior year.
- EPS (Weighted Average and Diluted) improved to $15960.8 in Q1 2026 per LKFT's latest filing, from $11.87 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $15960.8 in Q1 2026 and troughed at -$165241.6 in Q1 2025.
- A 5-year average of -$18658.7 and a median of $0.22 in 2024 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2022 and 2025: EPS (Weighted Average and Diluted) slumped 275.82% in 2022, then surged 2990.63% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$3.15 in 2022, then soared by 175.83% to $2.39 in 2023, then sank by 83.94% to $0.38 in 2024, then soared by 2990.63% to $11.87 in 2025, then soared by 134371.98% to $15960.8 in 2026.
- Business Quant data shows LKFT's EPS (Weighted Average and Diluted) at $15960.8 in Q1 2026, $11.87 in Q4 2025, and -$0.02 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 0.00 |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -0.61 |
| 10 | Lakefront Biotherapeutics | 9.64 Bn | 9.64 Bn | 1.97 Mn | 15,960.78 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15,960.78 |
| Dec 31, 2025 | 11.87 |
| Jun 30, 2025 | -0.02 |
| Mar 31, 2025 | -165,241.58 |
| Dec 31, 2024 | 0.38 |
| Jun 30, 2024 | 0.07 |
| Dec 31, 2023 | 2.39 |
| Dec 31, 2022 | -3.15 |
| Dec 31, 2021 | -0.84 |
| Jun 30, 2021 | -189,202.94 |
| Mar 31, 2021 | 158,571.43 |
| Dec 31, 2020 | -2,643.11 |
| Jun 30, 2020 | 2,300.84 |
| Dec 31, 2019 | -1,921.15 |
| Sep 30, 2019 | 78,700.00 |
| Dec 31, 2018 | 277.36 |
| Sep 30, 2018 | 53,003.57 |
| Dec 31, 2017 | -0.60 |
| Jun 30, 2017 | 0.71 |
| Mar 31, 2017 | -0.28 |